First Treatment for All Genotypes of Hepatitis C in Pediatric Patients Granted FDA Approval
April 30th 2019The safety and efficacy of the glecaprevir and pibrentasvir in pediatric patients was evaluated during clinical trials of 47 patients with genotype 1, 2, 3 or 4 HCV infection without cirrhosis or with mild cirrhosis.
Read More
Study Shows Drug May Be New Treatment Option for Pediatric Patients with T2D
April 29th 2019Novo Nordisk announced the results of the ELLIPSE trial, which examined efficacy and safety and demonstrated superiority of liraglutide (Victoza) injection 1.8 mg vs placebo, in a presentation at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting in Baltimore, MD, on Sunday.
Read More
FDA Approves Drug to Prevent Serious Cardiovascular Events
April 29th 2019High levels of ‘bad’ cholesterol, also known as low-density lipoprotein cholesterol (LDL-C), increase patients' risk for serious CV events such as heart attack or stroke. Adults who experience a heart attack or stroke have an approximately 1 in t3 chance to have another CV event.
Read More
Pediatric Lupus Treatment Receives FDA Approval
April 27th 2019This is the first time that the FDA has approved a treatment for pediatric patients with SLE. Belimumab has been approved for use in adult patients since 2011. GSK’s application for belimumab use in pediatric patients was granted the FDA’s Priority Review designation.
Read More
Health Care Professionals Bring Drug Shortage Concerns to Capitol Hill
April 26th 2019Last week, National Association of EMS Physicians members joined with other health care professionals on Capitol Hil to bring attention to the issue of drug shortages, as emergency medical facilities across the country are forced to severely restrict use of certain IV fluids, anti-nausea medications, airway management medications, and other essential emergency medications (EEMs).
Read More
Teva Recalls 35 Lots of Bulk Losartan Potassium Tablets
April 26th 2019According to Teva, this recall was initiated by detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) – found in 6 lots of active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited that is above the FDA’s interim acceptable exposure limit.
Read More
ASHP Joins National Academy of Medicine Action Collaborative on Countering the US Opioid Epidemic
April 25th 2019The mission of the Action Collaborative is to convene and catalyze public, private, and nonprofit stakeholders to develop, curate, and disseminate multisector solutions designed to reduce opioid misuse and improve outcomes for individuals, families, and communities affected by the opioid crisis.
Read More